PCSK9 inhibitors constitute a relatively new class of drugs designed to lower LDL-C levels, and they have been utilized in conjunction with statins and ezetimibe for patients at very high CV risk, particularly those engaged in secondary prevention and those with familial hypercholesterolemia [FH] and additional risk factors, who have not achieved prespecified target LDL-C levels [7]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.